Ocular Therapeutix reported second quarter 2026 financial results with total net revenue of $13.5 million and a net loss of $(78.8) million, or $(0.35) per share. The company holds $598.6 million in cash as of June 30, 2026, providing runway into 2028. Key business highlights include plans to submit a New Drug Application for AXPAXLI in wet AMD by Q4 2026 following positive FDA alignment. The company also announced amendments to the SOL-R and HELIOS-3 clinical trial protocols to optimize development pathways.

At its 2026 Annual Meeting, Ocular Therapeutix, Inc. stockholders approved an amendment to its 2021 Stock Incentive Plan to increase the number of shares issuable under the plan by 10,000,000 shares. The Board appointed Jason Robins as Chief Financial Officer, whose annual base salary will increase to $535,100 effective July 1, 2026, with a 45% target cash bonus. Ocular Therapeutix, Inc. is a biopharmaceutical company that develops and commercializes ophthalmic therapeutic products.